2004
DOI: 10.1007/s00535-004-1509-4
|View full text |Cite
|
Sign up to set email alerts
|

Why is leukocytapheresis effective in inflammatory bowel diseases?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2012
2012
2012
2012

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
1
0
0
Order By: Relevance
“…Previous reports suggested that LCAP was safe with few and minor adverse effects when used for some refractory autoimmune diseases [23, 24]. Interestingly, the counts of WBC and PMN decreased rapidly following LPS injection, which was consistent with an other report [25].…”
Section: Discussionsupporting
confidence: 90%
“…Previous reports suggested that LCAP was safe with few and minor adverse effects when used for some refractory autoimmune diseases [23, 24]. Interestingly, the counts of WBC and PMN decreased rapidly following LPS injection, which was consistent with an other report [25].…”
Section: Discussionsupporting
confidence: 90%